BAYER and DIAGNOS Join Efforts Against Diabetes

BROSSARD, QUEBEC--(Marketwired - Nov. 18, 2015) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today a contract for diabetic macular edema, diabetic retinopathy screening with BAYER. DIAGNOS shall provide a fully turn-key screening service to benefit thousands of diabetic patients in hospitals and clinics of three cities in Colombia: Cali, Ibagué and Bogotá D.C. Screening shall be offered to diabetics affiliated to their health entities whom shall test the impact of including preventive screening programs into their 1st level clinics that attends the gross of the diabetic population in the country.

Diabetic retinopathy along with Macular Edema are the most common diabetic eye diseases and the leading cause of blindness around the world. It is a treatable disease that - as with most diseases - has a higher treatment success rate in its earlier stages. However, there are generally no symptoms until the disease has progressed to more severe stages, making early detection methods critical by helping the prevention of vision loss.

"We are excited to start our new commercial relationship with BAYER and begin screening for diabetic macular edema and retinopathy. Following the expected success of this project, we intend to expand the scope of services offered through this pharmaceutical company into other Latin America countries," said André Larente, President & CEO at DIAGNOS.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.

Forward-looking information

This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these
statements.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.